The trial of semaglutide included 3,297 patients with type 2 diabetes, 83% of whom had established cardiovascular disease, chronic kidney disease, or both.
The Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) trial, which was funded by Novo Nordisk and the National Institutes of Health, randomized 9,340 patients ages 50 years and older to 1.8 mg of
The findings may reassure prescribers of dipeptidyl peptidase-4 inhibitors that the drug class does not significantly increase the risk of adverse pancreatic outcomes compared with other second-line therapies, study authors said.
The results highlight the importance of psychosocial interventions for at-risk patients, they concluded.
A study conducted in Australia found that general practitioners with specialization in diabetes care and subspecialist-led clinics reduced HbA1c levels by similar amounts in patients with complex type 2 diabetes.
In a retrospective observational study, patients with prediabetes were assigned to a risk category for diabetes based on presence and severity of insulin resistance, impaired beta-cell function, and hyperglycemia, then treated accordingly.
Among patients with coronary artery disease, severity and frequency of hypoglycemia were associated with increased levels of high-sensitivity cardiac troponin T, although the association was attenuated in adjusted analyses.
Adults with type 1 and type 2 diabetes should aim to spend more than 70% of each day in the target range of 70 to 180 mg/dL (3.9 to 10.0 mmol/L), which corresponds to an HbA1c level of about 7%, the consensus report said.
The studied risk factors were HbA1c level, LDL cholesterol level, presence of albuminuria, smoking status, and blood pressure.
The findings underscore the urgency of early diagnosis of diabetes and the consequences of failing to achieve near-normal glycemia soon after patients are diagnosed, according to the study authors.